Literature DB >> 21353885

The regulation and functions of activin and follistatin in inflammation and immunity.

Mark P Hedger1, Wendy R Winnall, David J Phillips, David M de Kretser.   

Abstract

The activins are members of the transforming growth factor β superfamily with broad and complex effects on cell growth and differentiation. Activin A has long been known to be a critical regulator of inflammation and immunity, and similar roles are now emerging for activin B, with which it shares 65% sequence homology. These molecules and their binding protein, follistatin, are widely expressed, and their production is increased in many acute and chronic inflammatory conditions. Synthesis and release of the activins are stimulated by inflammatory cytokines, Toll-like receptor ligands, and oxidative stress. The activins interact with heterodimeric serine/threonine kinase receptor complexes to activate SMAD transcription factors and the MAP kinase signaling pathways, which mediate inflammation, stress, and immunity. Follistatin binds to the activins with high affinity, thereby obstructing the activin receptor binding site, and targets them to cell surface proteoglycans and lysosomal degradation. Studies on transgenic mice and those with gene knockouts, together with blocking studies using exogenous follistatin, have established that activin A plays critical roles in the onset of cachexia, acute and chronic inflammatory responses such as septicemia, colitis and asthma, and fibrosis. However, activin A also directs the development of monocyte/macrophages, myeloid dendritic cells, and T cell subsets to promote type 2 and regulatory immune responses. The ability of both endogenous and exogenous follistatin to block the proinflammatory and profibrotic actions of activin A has led to interest in this binding protein as a potential therapeutic for limiting the severity of disease and to improve subsequent damage associated with inflammation and fibrosis. However, the ability of activin A to sculpt the subsequent immune response as well means that the full range of effects that might arise from blocking activin bioactivity will need to be considered in any therapeutic applications.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21353885     DOI: 10.1016/B978-0-12-385961-7.00013-5

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  56 in total

Review 1.  Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.

Authors:  Barbara Jung; Jonas J Staudacher; Daniel Beauchamp
Journal:  Gastroenterology       Date:  2016-10-20       Impact factor: 22.682

2.  Imbalance of Amniotic Fluid Activin-A and Follistatin in Intraamniotic Infection, Inflammation, and Preterm Birth.

Authors:  John T Hardy; Irina A Buhimschi; Megan E McCarthy; Guomao Zhao; Christine A Laky; Lydia L Shook; Catalin S Buhimschi
Journal:  J Clin Endocrinol Metab       Date:  2016-05-09       Impact factor: 5.958

3.  Cryptotanshinone reverses reproductive disturbances in rats with dehydroepiandrosterone-induced polycystic ovary syndrome.

Authors:  Yanqiu Xia; Pei Zhao; Hongli Huang; Yuan Xie; Rong Lu; Li Dong
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

Review 4.  The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer.

Authors:  Darcie D Seachrist; Ruth A Keri
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

5.  Activin A is stimulated by tumor necrosis factor-alpha and modulates collagen gene expression in human amniotic cells.

Authors:  Y Abe; M Komatsubara; M Saito; M Toda; H Shinozaki; T Tamura; Y Kasahara; H Sedakata; T Minegishi
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

6.  Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans.

Authors:  Athanasios D Anastasilakis; Stergios A Polyzos; Elpida C Skouvaklidou; Georgios Kynigopoulos; Zacharias G Saridakis; Aggeliki Apostolou; Georgios A Triantafyllou; Thomai Karagiozoglou-Lampoudi; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-07-08       Impact factor: 8.694

Review 7.  Beyond TGFβ: roles of other TGFβ superfamily members in cancer.

Authors:  Lalage M Wakefield; Caroline S Hill
Journal:  Nat Rev Cancer       Date:  2013-05       Impact factor: 60.716

8.  ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Authors:  Sarah J Hatsell; Vincent Idone; Dana M Alessi Wolken; Lily Huang; Hyon J Kim; Lili Wang; Xialing Wen; Kalyan C Nannuru; Johanna Jimenez; Liqin Xie; Nanditha Das; Genevieve Makhoul; Rostislav Chernomorsky; David D'Ambrosio; Richard A Corpina; Christopher J Schoenherr; Kieran Feeley; Paul B Yu; George D Yancopoulos; Andrew J Murphy; Aris N Economides
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

9.  γ-Tocopherol supplementation of allergic female mice augments development of CD11c+CD11b+ dendritic cells in utero and allergic inflammation in neonates.

Authors:  Hiam Abdala-Valencia; Frank Soveg; Joan M Cook-Mills
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-01-22       Impact factor: 5.464

10.  Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Laura F Newell; Todd E DeFor; Corey Cutler; Michael R Verneris; Bruce R Blazar; Jeff S Miller; Joseph H Antin; Alan Howard; Juan Wu; Margaret L MacMillan; Angela Panoskaltsis-Mortari; Daniel J Weisdorf; Shernan G Holtan
Journal:  Biol Blood Marrow Transplant       Date:  2019-11-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.